

PROCHLORPERAZINE (*Stemetil*) (C)

(Revised: November 2015)



TYPE: Phenothiazine antiemetic [S4]

PRESENTATIONS: 12.5mg in 1ml – ampoule

ACTIONS: Acts on several neurotransmitter systems:

1. antidopamine action
2. alpha-adrenergic antagonism
3. potentiates noradrenaline
4. weak anticholinergic and antihistamine effects
5. weak serotonin antagonism

Onset IM: limited data.
Duration IM: limited data – likely to be prolonged.

| | | |
|-------------|---|-----------|
| USE: | ICP For the treatment (only) of nausea and vomiting from a variety of vestibular causes, including: motion sickness, migraine, vertigo and labyrinthitis | AP |
|-------------|---|-----------|

ADVERSE EFFECTS:

- Gastrointestinal:* constipation, dry mouth
- Nervous system:* drowsiness, extrapyramidal symptoms
- Cardiovascular:* hypotension, ECG changes (especially QT prolongation)
- Respiratory:* respiratory depression

CONTRA-INDICATIONS:

- Known hypersensitivity to phenothiazines
- CNS depression
- Shock from any cause, or other circulatory compromise
- Not for use in pregnancy
- Paediatric patients (<18 years old)
- Not to be given in conjunction with intravenous amiodarone
- Previous oral prochlorperazine within last 8 hours

continues over

PROCHLORPERAZINE (*Stemetil*) (C) – cont.



PRECAUTIONS:

1. Renal dysfunction
2. Parkinson's disease
3. Myasthenia gravis
4. Epilepsy
5. Caution in elderly – increased risk of dystonic reactions

DOSES:

ADULT:

| | | |
|------------|--|-----------|
| ICP | 12.5mg deep IMI. <i>Single dose only.</i> | AP |
|------------|--|-----------|

PAEDIATRIC (<18 years old):

| | | |
|--|-----------|--|
| | Not used. | |
|--|-----------|--|

SPECIAL NOTE:

Patients who are administered prochlorperazine are not to be left at home, due to extensive adverse effect profile, potential symptom masking and extended half-life of the drug.